Soros Capital Management LLC Buys 4,230 Shares of Zoetis Inc. $ZTS

Key Points

• Soros Capital Management LLC increased its stake in Zoetis Inc. by 32.0%, acquiring an additional 4,230 shares, bringing their total holdings to 17,441 shares valued at approximately $2.87 million.
• Several other institutional investors have also significantly increased their stakes, with some reporting increases over 600% in the first quarter, leading to institutional ownership of 92.80% of the company.
• Zoetis recently reported an EPS of $1.76, exceeding market expectations, with quarterly revenue hitting $2.46 billion, marking a 4.2% increase year-over-year.

Soros Capital Management LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 32.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 17,441 shares of the company's stock after acquiring an additional 4,230 shares during the quarter. Soros Capital Management LLC's holdings in Zoetis were worth $2,872,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Portside Wealth Group LLC boosted its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. boosted its position in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after acquiring an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new position in shares of Zoetis during the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC boosted its position in shares of Zoetis by 117.6% during the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after acquiring an additional 3,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Trading Up 0.4%

ZTS stock traded up $0.60 during midday trading on Wednesday, reaching $155.39. The company's stock had a trading volume of 1,931,129 shares, compared to its average volume of 3,439,366. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a fifty day simple moving average of $153.53 and a two-hundred day simple moving average of $158.26. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm has a market capitalization of $68.87 billion, a price-to-earnings ratio of 26.75, a PEG ratio of 2.48 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.18% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.